A single course of anti-CD3 monoclonal antibody hOKT3γ1(ala-ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

Diabetes

Volumn 54, Issue 6, 2005, Pages 1763-1769

  Herold, Kevan C ^a,f   Gitelman, Stephen E ^b   Masharani, Umesh ^b   Hagopian, William ^c   Bisikirska, Brygida ^a   Donaldson, David ^d   Rother, Kristina ^e   Diamond, Beverly ^a   Harlan, David M ^e   Bluestone, Jeffrey A ^b  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; C PEPTIDE; CD8 ANTIGEN; FC RECEPTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY CD3; OKT 3; OKT 3ALPHA 1; UNCLASSIFIED DRUG;

ADULT; ALLOGRAFT; ARTICLE; AUTOIMMUNITY; CELL LOSS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; LYMPHOCYTE COUNT; MALE; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MUROMONAB-CD3; TIME FACTORS;

EID: 20044375937     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.6.1763     Document Type: Article

References (27)

1. Stiller CR, Dupre J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, von Graffenried B, Wolfe BM: Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223:1362-1367, 1984
2. Skyler JS, Lorenz TJ, Schwartz S, Eisenbarth GS, Einhorn D, Palmer JP, Marks JB, Greenbaum C, Saria EA, Byers V: Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team. J Diabetes Complications 7:224-232, 1993
3. Skyler JS, Rabinovitch A: Cyclosporine in recent onset type I diabetes mellitus: effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group. J Diabetes Complications 6:77-88, 1992
4. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, et al.: Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318:663-670, 1988
5. Buckingham BA, Sandborg CI: A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus. Clin Immunol 96:86-90, 2000
6. Bougneres PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF: Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39:1264-1272, 1990
7. Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, Nerup J: Cyclosporine nephrotoxicity in type 1 diabetic patients: a 7-year follow-up study. Diabetes Care 22:478-483, 1999
8. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S: Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319:599-604, 1988
9. Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T, Morris MA: Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 2:271-276, 1985
10. Chatenoud L, Thervet E, Primo J, Bach JF: Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 91:123-127, 1994
11. Chatenoud L, Primo J, Bach JF: CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158:2947-2954, 1997
12. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R: Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41:385-391, 1992
13. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L: TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9:1202-1208, 2003
14. Chatenoud L: OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 25:47-51, 1993
15. Chatenoud L: Humoral immune response against OKT3. Transplant Proc 25:68-73, 1993
16. Chatenoud L: Use of CD3 antibodies in transplantation and autoimmune diseases. Transplant Proc 26:3191-3193, 1994
17. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA: In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 200:16-26, 2000
18. Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA: A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57:1537-1543, 1994
19. Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR Jr: Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68:608-616, 1999
20. Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR: Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29:1907-1913, 2002
21. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698, 2002
22. Faber OK, Binder C, Marloissen J, Heding LG, Naithani VK, Kuzuya H, Blix P, Horwitz DL, Rubenstein AH: Characterization of seven C-peptide antisera. Diabetes 27 (Suppl. 1):170-177, 1978
23. Woo W, LaGasse JM, Zhou Z, Patel R, Palmer JP, Campus H, Hagopian WA: A novel high-throughput method for accurate, rapid, and economical measurement of multiple type 1 diabetes autoantibodies. J Immunol Methods 244:91-103, 2000
24. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA: Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J Clin Invest 111:409-418, 2003
25. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab 65:30-36, 1987
26. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C: Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics. Diabetologia 20:530-534, 1981
27. Foulds KE, Zenewicz LA, Shedlock DJ, Jiang J, Troy AE, Shen H: Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol 168:1528-1532, 2002